http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
-
Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Ionis Pharmaceuticals to present at upcoming virtual investor conferences
-
Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
-
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
-
Akcea (AKCA), Ionis (IONS) Announce Publication of L-T Clinical Data of TEGSEDI in Patients with Polyneuropathy Driven by hATTR Amyloidosis Demonstrating Sustained Improvements
-
Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
-
Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
-
Biogen (BIIB) Announces New SPINRAZA Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients
-
New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
-
Akcea Therapeutics (AKCA) Announces Appointment of New CFO
-
Akcea Announces Appointment of New Chief Financial Officer
-
Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
-
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
-
Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
-
Ionis reports first quarter 2020 financial results and recent business achievements
-
Akcea Reports Financial Results and Highlights for First Quarter 2020
-
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
-
Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
-
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
-
Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
-
Ionis Pharmaceuticals (IONS), Roche Report Complete Patient Enrollment of Global Phase 3 GENERATION HD1 study for Huntington's disease
-
Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
-
Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
-
Ionis Pharmaceuticals to present at upcoming investor conferences
-
Biogen (BIIB) Reports First Patient Treated with Higher Dose of SPINRAZA (nusinersen) in Phase 2/3 DEVOTE Study
-
Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
-
Akcea Therapeutics (AKCA) Announces Dr. Damien McDevitt as CEO
-
Akcea Therapeutics (AKCA) Announces Appointment of Dr. Damien McDevitt as CEO
-
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
-
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
-
Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
-
Dr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership team
-
Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
-
Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
-
Ionis Pharmaceuticals to present at upcoming investor conferences
-
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
-
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
-
Ionis provides fourth quarter and full year 2019 financial results
-
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
-
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
-
Ionis Pharmaceuticals to hold 2019 financial results webcast
-
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
-
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
-
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
-
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
-
Ionis Pharmaceuticals (IONS) treatment for Alexander disease granted orphan drug status from EMA
-
Ionis treatment for Alexander disease granted orphan drug status from EMA

